AYTU Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of 8.89% compared to Aytu BioPharma's net margin of 10.18%. Aytu BioPharma's return on equity of -20.38% beat Bristol-Myers Squibb's return on equity of -33.18%.

Aytu BioPharma has a consensus price target of --, signalling upside risk potential of 421.75%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $60.91 which suggests that it could grow by 5.02%. Given that Aytu BioPharma has higher upside potential than Bristol-Myers Squibb, analysts believe Aytu BioPharma is more attractive than Bristol-Myers Squibb.

Aytu BioPharma has a beta of -1.396, which suggesting that the stock is 239.633% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.628%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 4.14% to investors and pays a quarterly dividend of $0.60 per share. Aytu BioPharma pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out 59.12% of its earnings as a dividend. Bristol-Myers Squibb's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Aytu BioPharma quarterly revenues are $16.6M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.9B. Aytu BioPharma's net income of $1.5M is lower than Bristol-Myers Squibb's net income of $1.2B. Notably, Aytu BioPharma's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.13x versus 2.48x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of 8.89% compared to Aytu BioPharma's net margin of --. Aytu BioPharma's return on equity of -20.38% beat CEL-SCI's return on equity of --.

Aytu BioPharma has a consensus price target of --, signalling upside risk potential of 421.75%. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 997.08%. Given that CEL-SCI has higher upside potential than Aytu BioPharma, analysts believe CEL-SCI is more attractive than Aytu BioPharma.

Aytu BioPharma has a beta of -1.396, which suggesting that the stock is 239.633% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu BioPharma pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Aytu BioPharma quarterly revenues are $16.6M, which are larger than CEL-SCI quarterly revenues of --. Aytu BioPharma's net income of $1.5M is higher than CEL-SCI's net income of -$6.9M. Notably, Aytu BioPharma's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.13x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

enVVeno Medical has a net margin of 8.89% compared to Aytu BioPharma's net margin of --. Aytu BioPharma's return on equity of -20.38% beat enVVeno Medical's return on equity of --.

Aytu BioPharma has a consensus price target of --, signalling upside risk potential of 421.75%. On the other hand enVVeno Medical has an analysts' consensus of -- which suggests that it could grow by 488.24%. Given that enVVeno Medical has higher upside potential than Aytu BioPharma, analysts believe enVVeno Medical is more attractive than Aytu BioPharma.

Aytu BioPharma has a beta of -1.396, which suggesting that the stock is 239.633% less volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.219, suggesting its more volatile than the S&P 500 by 21.904%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu BioPharma pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

Aytu BioPharma quarterly revenues are $16.6M, which are larger than enVVeno Medical quarterly revenues of --. Aytu BioPharma's net income of $1.5M is higher than enVVeno Medical's net income of -$5.6M. Notably, Aytu BioPharma's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.13x versus 260.98x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

Telesis Bio has a net margin of 8.89% compared to Aytu BioPharma's net margin of -811.94%. Aytu BioPharma's return on equity of -20.38% beat Telesis Bio's return on equity of -151.32%.

Aytu BioPharma has a consensus price target of --, signalling upside risk potential of 421.75%. On the other hand Telesis Bio has an analysts' consensus of -- which suggests that it could grow by 16171.17%. Given that Telesis Bio has higher upside potential than Aytu BioPharma, analysts believe Telesis Bio is more attractive than Aytu BioPharma.

Aytu BioPharma has a beta of -1.396, which suggesting that the stock is 239.633% less volatile than S&P 500. In comparison Telesis Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Telesis Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu BioPharma pays -- of its earnings as a dividend. Telesis Bio pays out -- of its earnings as a dividend.

Aytu BioPharma quarterly revenues are $16.6M, which are larger than Telesis Bio quarterly revenues of $1.6M. Aytu BioPharma's net income of $1.5M is higher than Telesis Bio's net income of -$12.6M. Notably, Aytu BioPharma's price-to-earnings ratio is -- while Telesis Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.13x versus 0.04x for Telesis Bio. Usually stocks with elevated PS ratios are considered overvalued.